Central European Cooperative Oncology Group

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

Giorgio V. Scagliotti, Thomas Brodowicz, Frances A. Shepherd et al. · Journal of Thoracic Oncology · 2010 · 253 citations · Full text

Medicine, Oncology, Pharmacology +7

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt et al. · European Journal of Cancer · 2011 · 184 citations

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Gϋnter von Minckwitz, Fabio Puglisi, Javier Cortés et al. · The Lancet Oncology · 2014 · 146 citations

Medicine, Oncology, Pharmacotherapy +17

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego et al. · Annals of Oncology · 2020 · 133 citations · Full text

Medicine, Oncology, Pharmacology +15